TYROBP and osteosarcoma: To investigate the clinical benefits of TYROBP, we performed a Kaplan–Meier plotter analysis of the GDC TARGET-osteosarcoma dataset and found that osteosarcoma patients with high TYROBP expression exhibited better OS (HR = 0.14, P < .001) (Fig. 1C).